Literature DB >> 15572960

Parathyroid hormone for the treatment of osteoporosis.

Michael McClung1.   

Abstract

UNLABELLED: Imbalances in bone metabolism result in bone mass loss and skeletal fragility in postmenopausal women and older men. Most osteoporosis treatments decrease bone metabolism and prevent the progression of bone loss and architectural damage to the skeleton. Analogs of parathyroid hormone stimulate the formation of new bone and offer new options for managing osteoporosis. This review highlights the effects of parathyroid hormone on bone density and fracture risk in patients with osteoporosis and addresses several of the important issues pertaining to the use of these new agents in daily clinical practice. TARGET AUDIENCE: Obstetricians and Gynecologists, Family Physicians. LEARNING
OBJECTIVES: After completion of this article, the reader should be able to summarize the different mechanisms of action between parathyroid hormone analogues and antiresorptive drugs, to outline the effects of teriparatide treatment of patients with osteoporosis, and list the indications of teriparatide therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15572960     DOI: 10.1097/01.ogx.0000146584.12831.c9

Source DB:  PubMed          Journal:  Obstet Gynecol Surv        ISSN: 0029-7828            Impact factor:   2.347


  4 in total

Review 1.  Recombinant full-length parathyroid hormone (1-84).

Authors:  Marit D Moen; Lesley J Scott
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Treatment of osteoporosis with TheraCyte-encapsulated parathyroid cells: a study in a rat model.

Authors:  F-F Chou; S-C Huang; S-S Chen; P-W Wang; P-H Huang; K-Y Lu
Journal:  Osteoporos Int       Date:  2006-04-05       Impact factor: 4.507

3.  Effect of TheraCyte-encapsulated parathyroid cells on lumbar fusion in a rat model.

Authors:  Sung-Hsiung Chen; Shun-Chen Huang; Chun-Chung Lui; Tzu-Ping Lin; Fong-Fu Chou; Jih-Yang Ko
Journal:  Eur Spine J       Date:  2012-07-06       Impact factor: 3.134

4.  Teriparatide vs. alendronate as a treatment for osteoporosis: changes in biochemical markers of bone turnover, BMD and quality of life.

Authors:  Annalisa Panico; Gelsy Arianna Lupoli; Francesca Marciello; Roberta Lupoli; Marianna Cacciapuoti; Addolorata Martinelli; Luciana Granieri; Daniela Iacono; Giovanni Lupoli
Journal:  Med Sci Monit       Date:  2011-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.